New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin
Open Access
- 1 April 2005
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 144 (8) , 1017-1028
- https://doi.org/10.1038/sj.bjp.0706153
Abstract
The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing. British Journal of Pharmacology (2005) 144, 1017–1028. doi:10.1038/sj.bjp.0706153Keywords
This publication has 126 references indexed in Scilit:
- Minor Transplacental Passage of Fondaparinux in VivoNew England Journal of Medicine, 2004
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug InteractionsClinical Pharmacokinetics, 2003
- Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous MelagatranClinical Pharmacokinetics, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- An Economic Evaluation of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human ThrombogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplastyAmerican Heart Journal, 1995